Bortezomib will improve the level or influence of flibanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check. Increased flibanserin adverse results may perhaps take place if coadministered with a number of weak CYP3A4 inhibitors. B: Can be appropriate. Possibly animal experiments demonstrate no possibility but human experiments not available or https://indirax111lxi2.wikifordummies.com/user